Market Overview

UPDATE: Canaccord Genuity Downgrades Vical Following Allovectin Failure

Related VICL
Vical Posts Q1 Net Loss
US Stock Futures Slip; JPMorgan Earnings In Focus

In a report published Tuesday, Canaccord Genuity analyst Ritu Baral downgraded Vical (NASDAQ: VICL) from Buy to Hold, and lowered the price target from $7.00 to $1.40.

In the report, Canaccord Genuity noted, “Lowering to HOLD, $1.40 target on Allovectin Ph3 failure and program halt. We still see blockbuster potential for the Astellas-partnered CMV franchise (ASP0113, f.k.a. CymVectin; TransVax) given unmet need. Our $1.40 target is based on a pNPV analysis.”

Vical closed on Monday at $1.53.

Latest Ratings for VICL

Aug 2013CitigroupMaintainsBuy
Aug 2013Canaccord GenuityDowngradesBuyHold
Aug 2013Credit SuisseDowngradesOutperformNeutral

View More Analyst Ratings for VICL
View the Latest Analyst Ratings

Posted-In: Canaccord Genuity Ritu BaralAnalyst Color Downgrades Analyst Ratings


Related Articles (VICL)

Around the Web, We're Loving...